if i understood Ma correctly - BIOX had a $312K increase QoQ from last year and that is finally starting to reach critical mass. if they continue to accelerate growth in that area - that should provide an additional $1.5MM+ of revenues that was not present in 2012. the original acquisition was supposed to be accretive so there should be positive net income coming from those additional revenues on top of the GEHC.
Ma said in 1Q13 CC that they expected EECP sales to grow throughout the year. they were flat in 2Q13 and he did not reiterate his comments in the CC but he was also not asked about it.
any positive news concerning CMS reimbursement, new trial data with positive results in new indications (diabetes, Alzheimer's, ED, Parkinson's, ED, etc) and we will see that gap closed rather quickly ahead of positive year end.
Recent VASO News
- Form PREM14A - Preliminary proxy statements relating to merger or acquisition • Edgar (US Regulatory) • 03/06/2024 09:58:30 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 12/11/2023 07:10:05 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:00:38 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM